CDIO Cardio Diagnostics
- 0.905
- +0.178+24.42%
- 0.920
- +0.015+1.63%
Cardio Diagnostics News
Cardio Diagnostics Announces Publication of Study Showing That Its PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually
The Peer-Reviewed Publication Demonstrates the Potential Economic Benefits of the PrecisionCHD Test for the Detection and Management of Coronary Heart Disease, which is One of the Largest Cost Centers for Public
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index rising 0.3% and the Health Care Select Sector SPDR Fund (XLV) adding 0.4%. The iShares Biotechnology ETF (IBB) dec
Top Midday Decliners
Luna Innovations (LUNA) said its audit committee, after consultation with its management and external legal and financial advisers, concluded financial statements for some accounting periods "cannot b
Cardio Diagnostics Is Maintained at Speculative Buy by Benchmark
Cardio Diagnostics Is Maintained at Speculative Buy by Benchmark
Benchmark: Maintaining the Cardio Diagnostics Hldgs (CDIO.US) rating, adjusted from Speculative Buy to Specified Buy, and adjusted the target price from $4.00 to $1.35.
Benchmark: Maintaining the Cardio Diagnostics Hldgs (CDIO.US) rating, adjusted from Speculative Buy to Specified Buy, and adjusted the target price from $4.00 to $1.35.
Benchmark Maintains Speculative Buy on Cardio Diagnostics Hldgs, Lowers Price Target to $1.35
Benchmark analyst Bruce Jackson maintains Cardio Diagnostics Hldgs with a Speculative Buy and lowers the price target from $4 to $1.35.
Cardio Diagnostics Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/19/2024 29.81% Benchmark $4 → $1.35 Maintains Speculative Buy 06/15/2023 669.23% Benchmark → $8 Reitera
12 Health Care Stocks Moving In Monday's After-Market Session
GainersDynatronics (NASDAQ:DYNT) stock increased by 70.1% to $0.63 during Monday's after-market session. The company's market cap stands at $3.0 million. Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock r
Exponential Health Partners With Cardio Diagnostics For Cardiovascular Disease Prevention In Michigan
Exponential Health, an innovative concierge medicine practice in Michigan, adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests, marking a new era in personalized and preventive cardiac care.
Cardio Diagnostics Holdings Enters Into Nationwide Telehealth Agreement With Navierre; Terms Not Disclosed
Cardio Diagnostics Holdings Enters Into Nationwide Telehealth Agreement With Navierre; Terms Not Disclosed
Canopy Growth, Exact Sciences, Stereotaxis Among Healthcare Movers
Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology's 73rd Annual Scientific Session
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, announces that the Company will showcase its groundbreaking HeartRiskTM and Actionable Clinical IntelligenceTM
Sector Update: Health Care Stocks Lower Tuesday Afternoon
Health care stocks were declining Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each shedding about 0.7%. The iShares Biotechnology ETF (IBB) fel
Cardio Diagnostics Shares Rise as Partner University of Iowa Research Foundation Gets US Patent
Cardio Diagnostics' (CDIO) shares rose past 20% in recent Tuesday trading after the company said the US Patent and Trademark Office issued a notice of allowance to the University of Iowa Research Foun
Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces that the U.S. Patent and Trademark Office has issued a notice of allowance to University of Iowa Research Foundation ("UIRF") for U.S. Application No. 17,857,723 titled Compositions and Methods for Detecting Predisposition to Cardiovascular Disease, which is exclusively licensed to the Company from UIRF, and that was co-invented by Cardio Diagnostics' founders, Meesha Dogan, Ph.D., and Robert Philibert, MD Ph.D., the Chief Executive Officer and Chief Medical Officer of the Company, respectively. This is the second U.S. patent being issued in this patent family. Patents in this patent family have also been issued in the European Union, China, India, and Australia.
JAGX, BBAI and BNTC Among Mid-day Movers
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersChina SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 25.2% to $2.73 during Friday's pre-market session. The company's market cap stands at $1.5 million. MediciNova (NASDAQ:MNOV) stock inc
Cardio Diagnostics Holdings, Inc. Expands HeartRisk Platform Offering to Diverse Markets in Conjunction With Nationwide Rollout
Transformative Cardiovascular Risk Management Solutions Extend Beyond Traditional Sectors to Include Federal and State Correctional Facilities, Broker and Benefits Organizations, and Risk Bearing Providers. Cardio
Cardio Diagnostics Holdings, Inc. Expands Partnership With Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters
Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a retail healthcare setting on a walk-in basis. Cardio Diagnostics Holdings, Inc.
Market-Moving News for February 5th
FDMT: 86% | 4DMT Presents Interim Data From Randomized Phase 2 PRISM Clinical Trial Of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity In Wet AMDBRTX: 74% | BioRestorative
Analysis
Price Target
No Data
